Use of cells as therapeutic carriers has increased in the past few years and has developed as a distinct concept and delivery method. Cell-based vehicles are particularly attractive for delivery of biotherapeutic agents that are difficult to synthesize, have reduced half-lives, limited tissue penetrance or are rapidly inactivated upon direct in vivo introduction. Initial studies using cell-based approaches served to identify some of the key factors for the success of this type of therapeutic delivery. These factors include the efficiency of cell loading with a therapeutic payload, the means of cell loading and the nature of therapeutics that cells can carry. However, one important aspect of cell-based delivery yet to be fully investigated is the process of actual delivery of the cell payload in vivo. In this regard, the potential ability of cell carriers to provide site-specific or targeted delivery of therapeutics deserves special attention. The present review focuses on a variety of targeting approaches that may be utilized to improve cell-based therapeutic delivery strategies. The different aspects of targeting that can be applied to cell vehicles will be discussed, including physical methods for directing cell distribution, intrinsic cell-mediated homing mechanisms and the feasibility of engineering cells with novel targeting mechanisms. Development of cell targeting strategies will further advance cell vehicle applications, broaden the applicability of this delivery approach and potentiate therapeutic outcomes.
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Carriers are a practical means to improve therapeutic delivery
Ideal therapeutic agents act at the cellular or molecular level to specifically correct a defect. Despite the fact that efficient correction was achieved with many agents in vitro, physiological barriers and toxicity often limit the efficacy of these agents in vivo. Therefore, additional means are needed to facilitate delivery of these agents and restrict their activity to the target tissue. In the context of drug delivery, the importance and value of carrier systems has long been recognized. Drug carriers are diverse in nature and include liposomes, albumin microspheres, synthetic polymers, protein-DNA complexes and other substances. 1, 2 All carriers are intended to compensate for the limitations of the drug alone, including toxicity, poor absorption and release, short half-life and lack of tissue specificity. Carriers can considerably enhance the pharmacokinetic properties, biodistribution, availability, activity and overall efficacy of any therapeutic. The need for appropriate carriers has also been recognized in the context of gene therapy applications. The most efficient therapeutic gene carriers are typically derived from biological agents, such as viruses, bacteria, phages. To this end, mammalian cells recently received increased attention as carriers.
Cells have distinct advantages as carriers of complex therapeutics
Compared to other carrier systems, cell-based carriers have additional characteristics that can be utilized for therapeutic advantage. Cell-based vehicles are particularly attractive for delivery of complex biotherapeutic agents that are difficult to synthesize, have reduced halflives or have limited tissue penetrance. Cells can protect therapeutics en route from inactivation by bodily defense mechanisms. Cells can also serve as production factories to produce and correctly process these agents in their most physiological form. In this regard, genetically engineered cells have been used to produce and secrete a wide range of transgene products including factor IX, 3 growth hormone, 4 erythropoietin, 5 ciliary neurotrophic factor 6 and dopamine. 7 Increased utilization of cells as vehicles has helped to identify key factors that are critical and distinct for this method of therapeutic delivery. Factors such as the efficiency of cell loading, the means of cell loading and the nature of the therapeutics that cells can carry have received much scientific attention and are described in more detail elsewhere. 8, 9 Another important issue to consider is the behavior of the cells when they are introduced into the body. In applications where cells are used as therapeutic factories, their ability to disseminate throughout the body is of little importance. To this end, producer cells are often transplanted as 'artificial glands' immobilized in matrixes or supportive devices that keep cells at the transplant site. 10 In this mode the biotherapeutics produced by the cells are intended to act locally at the site of cell implantation, or to act remotely if secreted into circulation. In contrast to immobilized cell transplantation, numerous applications require delivery of the therapeutic agent to key sites of pathology that generally exist remotely from the site of injection. Some cell types can mediate delivery of therapeutics to tissues that are inaccessible to other carriers or have the potential to enhance delivery of the therapeutics to the site of pathology, thereby presenting an opportunity for targeted delivery.
Targeted delivery enhances therapeutic efficacy
Coupling therapeutics to a carrier often achieves only protective function and does not necessarily improve the specificity of delivery. Targeted delivery of therapeutics is another strategy to enhance the efficiency of treatment. Targeting may require careful design or additional modifications applied to the carrier itself. Targeted drug delivery as a 'magic bullet' concept was introduced as early as 1908 by Paul Ehrlich and conceptualizes delivery systems that are able to increase the concentration of the drug in the site of interest, such as tumors. Targeting improves treatment efficacy by directly increasing the localized concentration of the therapeutic agent and indirectly via limiting sequestration, dilution or inactivation of the therapeutic in nontarget tissue. In toto, the act of targeting a therapeutic agent should greatly reduce the overall dose required for treatment and limit toxicities in nontarget tissues. Gene-based therapeutics would similarly benefit from targeted delivery approaches, especially if localized gene expression is required. In this regard, much attention has been focused on evaluating the biodistribution of gene delivery vectors as well as modification of these vectors to change their native tropism and biodistribution patterns. 11, 12 With the recent interest in cell-based vectors, it is intriguing to investigate how they might be amenable to targeting approaches and which targeting approaches are applicable to the cell-based vectors. This interest is fueled by the discovery that some cell types have an inherent ability to home to clinically relevant target tissues. 13, 14 Additional interest has been generated by several recent reports of using infected cell vehicles as a strategy to improve oncolytic virus delivery to disseminated in vivo tumor models. [15] [16] [17] The cell-mediated improvements documented in these reports are mediated by reduced virus neutralization and sequestration by host factors. However, additional gains are achieved using cell types with active mechanisms for vascular egress, or preferential tumor-homing activities. 16, 17 These data suggest that strategies that confer additional targeting on cell vehicles will further improve therapeutic delivery to sites of pathology. In addition, the limited in vivo ability of many 'targeted' viruses to reach the intended sites has re-emphasized the importance of coupling viral delivery with a 'Trojan horse'-based cell strategy and incorporation of several targeting layers into the cell-virus system. 18, 19 Therefore, it is important to evaluate which targeting approaches are applicable to the cell-based vectors in general, as well as to determine how various cell types are amenable to these targeting strategies.
Although the advantages of cell targeting are obvious, the practical implementation of cell targeting strategies in complex in vivo systems is not straightforward. In this review we attempt to summarize targeting strategies that can be applied to cell carriers for site-specific localized delivery of therapeutics (Figure 1 ). Both the native means of targeting and artificial strategies to target and engraft cell vehicles to specific sites or tissues will be described. In addition, the key issues that may affect different cell subsets as therapeutic vehicles will be considered in terms of their ability to home to specific sites, their ability to circulate and their normal biodistribution after systemic injection. Considering the breadth of the scope, our task is not to comprehensively cover all areas related to cell targeting but rather bring together these different areas of research in an attempt to identify key factors that may lead to the success or failure of cell vehicle strategies.
Physical targeting strategies
Strategies where increased cell concentration is achieved via the help of appropriate devices or procedures can be referred as physical targeting. Logically, getting therapeutics, cell vehicles included, closer to the intended target site will immediately help to overcome mechanical and physiological barriers that reduce the effective dose achieved. Therefore, the most straightforward way to increase the local concentration of cells is to apply it directly to the site where the therapeutic action is needed. However, the simplicity of this concept can be misleading. Direct accessibility to most organs requires either open surgical procedure, or use of guiding devices, such as catheters. However, even when physical targeting is possible, other factors must be taken into consideration. For instance, it has been noted that heart beating presents a serious problem for cell retention even if they are introduced via catheter. 20 Therefore, other factors may limit therapeutic efficacy even when direct cell introduction is possible. Despite the technical challenges, local or direct introduction of therapeutics or therapeutic carriers could be an effective means of targeting. Catheters or other devices allow cell introduction directly into the parenchyma or blood supply of a particular organ or within body cavities (peritoneum, pleura). Physical targeting strategies have been used to directly introduce cell carriers in various brain, 21, 22 heart 23 and wound 24 models and has resulted in positive therapeutic outcomes. In some cases current technological advancements allow diseased areas to be mapped, allowing guided instruments apply therapeutic cells directly to the diseased spot such as heart infarction. 25 Instrument-guided devices allow cell introduction to be feasible for a range of target organs, including heart, trachea, lung and brain.
Another recently proposed method of physical cell targeting involves the use of magnetic fields to attract 31 evaluated whether iron oxide-labeled MSCs could be physically targeted in rat models. External magnets placed over the liver of the transplanted rats specifically increased the concentration of loaded MSCs in the liver of these animals. The feasibility of magnetically targeting bone marrow (BM) stromal cells to spinal cord injuries has also been demonstrated in animal models. 30 The cells in this study were injected into the cerebrospinal fluid as minimally invasive alternative to direct local injections into spinal cord. A magnetic field was then applied and greater numbers of the labeled cells aggregated on the surface of the spinal cord nearest the magnetic field. Magnetic labeling has also been evaluated as a strategy for targeting endothelial cells to the steel surfaces of intra-arterial stents. 32 Although in vitro and in vivo findings proved sufficient cell motility toward applied physical targeting and the ability of labeled cells to concentrate at the projection of magnetic forces, practical utility of this type of targeting has yet to be demonstrated.
Physiological targeting strategies
Physiological targeting is based on natural physiological forces or mechanisms that govern cell concentration in specific sites, organs or systems. Erythrocyte-based therapeutic delivery is a good illustrative example of how the physiology of in vivo cell turnover can be utilized for a cell targeting advantage. The use of erythrocytes as physiologically targeted carriers was proposed decades ago and has only recently advanced to the clinic. 33, 34 The biological properties of erythrocytes favor their use in cell vehicle strategies; they are readily available in great quantities, they are biocompatible with type-matched recipients, and they have a considerably long life span in circulation. Two physiological processes are exploited for erythrocyte-based therapeutic delivery: their ability to freely circulate throughout the vasculature and the natural mechanism by which senescent erythrocytes are removed from circulation. 35 The first property makes these cells ideal vehicles for systemic delivery, as they have virtually unrestricted access to all vascularized tissues or organs in the body. Senescent or damaged erythrocytes are opsonized and phagocytosed by cells of Figure 1 Cell vehicle targeting strategies. Different targeting strategies can be used to localize cell vehicles to the tissue of interest. Physical targeting embodies the use of devices, such as catheters, to position the cells where they are needed. Physiological targeting takes advantage of natural forces or mechanisms that route transplanted cells to specific sites or organs. Cells move slowly through microcapillaries. Therefore, based on the infusion site, cells can be physiologically targeted to the microcapillary beds of specific tissues. Biological targeting strategies embody a range of molecular techniques to target cell vehicles. Cells with inherent trafficking pathways can be utilized to deliver therapeutics to the specific tissues they infiltrate. Adapters and artificial receptors establish affinity-based retention of cell vehicles to the target. Lastly, local factors that induce survival or proliferation can increase the number of cell vehicles at the target site.
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utilized this clearance mechanism to physiologically target erythrocytes loaded with an anti-HIV pro-drug to the macrophage compartment. This effectively protected the targeted macrophages from 'de novo' HIV infection. Detailed knowledge of RES uptake mechanisms can be also used to augment erythrocyte targeting advantages. In this regard, the fact that the chemical composition of the erythrocyte membrane affects recognition and phagocytosis by macrophages led to the evaluation of a series of agents that influence the integrity or composition of erythrocyte membranes. 37 To this end, pre-exposing the carrier erythrocytes to thermal shock, oxidative compounds, neuraminidase or proteolytic enzymes all improved the targeting of carrier erythrocytes to the RES. 38 The fact that naturally senescent or damaged erythrocytes are mainly trapped in the spleen and liver can also be exploited to target therapeutic delivery to these organs. Further, some erythrocyte modifications skew erythrocyte uptake toward a particular organ; coating erythrocytes with immunoglobulin G (IgG) antibodies results in preferential targeting to spleen, whereas IgM antibodies results in their preferential uptake in the liver. 38 The degree of membrane damage was also shown to affect the proportion of erythrocytes sequestered in the spleen and liver.
Physiological processes that move or restrict cell movement can also be utilized to target cell vehicles in vivo. Utilization of injected cell accumulation or concentration at the borders of physiological barriers (capillary net, blood-brain barrier) can also be viewed as physiological targeting. This type of targeting is usually driven by physical forces, such as blood flow, that move the cells, rather than by cell-mediated movement. Cells tend to become trapped in the capillary beds of the first organs they pass through. It is well known that lungs represent the first-pass mechanical barrier to many systemically introduced cell types. Nevertheless, this effect can be conveniently utilized to target cell-mediated therapeutic delivery to the lungs. 14, 39, 40 In general, physiological processes that retain cells can be utilized as a means to target the tissues that accumulate these cells.
Recognition of the physiological barriers that specific cell types encounter in relation to their route of introduction is important, since these barriers can also easily confine or diminish downstream cell-mediated targeting efforts. Some of these barriers can be avoided or overcome. Lung entrapment can be avoided by introducing the cells into the desired organ's arterial blood supply, or by using vasodilatory agents as pretreatment. In addition to cell size, other factors such as cellular rigidity can influence the level of cell entrapment in capillaries. It has also been shown that ex vivo manipulation or activation can affect the viscoelastic properties of cells, making it more difficult for the injected cells to traverse capillary beds. 41 Although any systemically injected cell population will see the capillary bed of the lungs first, the retention time can vary considerably depending on the cell type. For instance, immune cells can be cleared from the lungs in as little as 2-8 h, 42 while a majority of transplanted MSCs can still be detected in the lungs as long as 48 h after injection. 43 Overall, physical and physiological targeting may be valuable tools to increase the concentration of cell carriers in tissues of interest. However, even when cells are directly guided into the parenchyma of an organ, they may remain at the injection site and fail to reach the diseased sites within that organ. Thus, additional mechanisms of cell targeting may be needed in conjunction with direct (intraorgan or intracavital) cell administration. Demands for targeting stringency are increased upon systemic introduction of cell carriers, especially considering all of the physiological barriers that have to be overcome for the cells to reach the desired destination. This is particularly true when the pathology is widespread, such as metastatic lesions or genetic disorders that affect all cells of specific cell type.
Biological targeting strategies
We consider biological targeting as an active process in which the cells themselves are engaged in the processes that lead to their specific localization in vivo. Three main strategies have been envisioned to attain biological targeting of cell vehicles: (1) hijacking native cell-homing machinery; either by choosing cell vehicles that naturally traffic to the target site, or by ectopic expression of the homing machinery in the cell vehicle of choice, (2) expression of factors that specifically enhance cell vehicle survival or proliferation in the target site and (3) expression or coating the vehicles with molecules that have affinity for the target site. Cell therapy studies have previously established the importance of using cells that are easily isolated, expanded and manipulated ex vivo. As discussed above for physiological targeting strategies, the capacity to circulate is an additional characteristic that is important for cell targeting strategies. In this capacity, the cells are naturally circulating, conditionally circulating or resident. Naturally and conditionally circulating cell types have the capacity to traffic to different regions of the body. The various trafficking routes they utilize and their destinations are specified by tightly regulated proteins on both the trafficking cells and the cells comprising their target tissue.
Cells have natural trafficking machinery
Cells have natural trafficking machinery that they utilize for migration. Much of our current understanding of this cell trafficking machinery comes from characterization of leukocyte and progenitor cell trafficking pathways. These cells circulate through the vasculature and home to specific tissues. However, sequential signaling events and cell-cell interactions act to specify the timing and the type of tissues each of these cell types can infiltrate (reviewed by Muller 44 ). Initially high-tensile interactions are initiated between the circulating cell and the vascular endothelial cells of the target tissue. These intercellular interactions are mediated by a family of proteins called selectins that bind corresponding sialyl Lewis X -related oligosaccharide ligands. 45, 46 Selectin binding causes the circulating cells to roll along the wall of the vasculature. Rolling slows cell movement to allow secondary binding events to establish firm adhesion. The firm adhesion process is initiated by small molecules called chemokines. Various tissues secrete specific chemokines into the vascular lumen, either constitutively or in response to inflammation, and cells with the appropriate receptors detect these chemokines as they roll by (reviewed by Olsen et al. 47 and Le et al. 48 ). Chemokine receptor binding triggers signaling events that activate firm adhesion molecules, called integrins, on the surface of the circulating cells. Upon activation, integrins initiate strong adhesive contacts with intercellular adhesion molecules on endothelial cell surface. 49, 50 The resulting firm cellcell adhesion stops cell rolling and allows the cells to establish additional interactions that facilitate transmigration into the parenchyma of the tissue. These natural mechanisms for cell trafficking must be considered for cell-based delivery strategies. Knowledge of the specific molecules that mediate these homing pathways may be utilized to confer novel targeting properties to cell types of interest.
Circulating cell types are ideal for biological targeting strategies
The selectivity of natural cell trafficking pathways suggests that circulating cell types may be ideal for biological targeting strategies. The concerted interaction and specific combination of chemokine receptors, selectins, integrins and their corresponding ligands, all act to specify the type of cells that traffic to a given tissue. The tight regulatory control over this process prevents aberrant cell distribution. It also indicates that attempts to confer novel homing properties to cells that normally lack trafficking machinery will be difficult. Many leukocyte and stem cell subsets home to distinct tissues. Therefore, based on the target tissue, different cell types might be utilized to deliver the therapeutics. An understanding of where various circulating cell types localize will be important for their realization as potential biologically targeted vehicles.
Lymphocytes. Lymphocytes have well-recognized potential for biological targeting strategies, due to the wide range of tissues they infiltrate. However, lymphocyte localization patterns differ according to their lineage, maturity and activation state. 51, 52 Common lymphoid progenitors in the BM give rise to immature B-and T-cell progenitors. Maturation of B-and T-cell subsets occurs in different parts of the body; B-cell progenitors mature in subcompartments of the BM, whereas T-cell progenitors migrate to and mature in the thymus. Upon maturation, naive lymphocytes enter the blood stream and their unique trafficking components direct their constitutive extravasation across high endothelial venules into the secondary lymph organs. These naive cells continually circulate through the blood and lymph until they either encounter antigen or apoptose. Upon activation with antigen and an appropriate helper T cell, B cells proliferate in lymphoid follicles, where they further differentiate into memory B cells or plasma cells. Memory B cells continue circulating through the B-cell zones of secondary lymphoid tissues, whereas the plasma cells preferentially migrate into the BM or mucosal tissues. T cells are activated when they meet dendritic cells presenting their cognate antigen in the context of appropriate costimulatory signals. Effector T cells then primarily traffic through nonlymphoid tissues and inflammatory sites. 53 The dendritic cells in specific lymphoid organs can also influence the tissues to which the activated lymphocytes home. For example, mucosal and intestinal dendritic cells induce expression of gut-homing trafficking machinery. 53, 54 This mechanism ensures that the cells are localized to tissues where they are more likely to encounter their cognate antigen. Once in these tissues, localized inflammatory signals then further direct the cells toward antigen. Thus, the tissue source from which activated lymphocytes are obtained will influence the types of tissues the cells home to upon reinfusion.
Various T-cell subsets have long been evaluated as targeted immunotherapeutic agents for cancer treatment. 55 T cells are particularly attractive because they have inherent potential for tumor-directed toxicity. Tumor-infiltrating T cells can be isolated, characterized and amplified ex vivo.
56 These cells express the T cell receptor (TCR), which has the potential to recognize tumor-specific antigens presented in major histocompatibility complex (MHC)-CI molecules. Further, the fact that they are isolated from tumors suggests they have the capacity to home to and infiltrate tumors upon reinfusion. Other T-cell populations can illicit cytotoxic effects in the absence of MHC restriction. These include lymphokine-activated killer cells and NK cells, both of which are efficiently isolated and expanded from peripheral blood leukocyte pools. Since all of these populations rely on cell-cell interactions to induce cytotoxicity, their therapeutic utility depends on their ability to traffic to target sites. The tumor-homing pathways of T cells are still being elucidated, but involvement of chemokine receptors is apparent, since pertussis toxin inhibits cytotoxic T lymphocyte (CTL) homing, but not antigen recognition and stimulation. 57 Recently, Brown et al. 58 compared the chemokine profile of tumors with high levels of lymphocytic infiltration to those without and reported CCL2 as the major tumorsecreted chemokine involved in adoptively transferred CTL homing. However, previous studies indicate that CCL2 can suppress endogenous CTL production. 59, 60 A number of other chemokines, such as CXCL12, CCL18 and CCL21 have also been shown to participate in 61 or promote 62 T-cell homing into tumor environments. The extent to which homing activities contribute to CTL accumulation in tumors is difficult to distinguish from other factors that result in their increased accumulation in tumors. Antigen-specific T-cell numbers are also likely to increase in antigen-rich sites due to TCR-mediated proliferation or retention of the cells. Nevertheless, CTL have been evaluated for treatment of melanomas and virus-induced lymphomas. These studies demonstrate the utility of T cells as biological targeting agents.
Despite their inherent capacity to infiltrate tumors and mediate toxicity, T-cell therapy may be more effective if the cells are also used as therapeutic delivery vehicles. The tumor environment is rich in factors that limit T-cell infiltration, 63 ,64 activation 65 and function. 66 Therefore, to maximize efficacy, the cells reaching the tumor site should deliver a payload that can be amplified locally. In this regard, several groups have utilized T cell-mediated tumor homing as a means to deliver oncolytic viruses in animal tumor models. 17, 18, [67] [68] [69] The T cells serve to deliver the virus, limit nonspecific viral sequestration and localize viral release within the tumor. Improved viral access to tumor models has been achieved with both antigen-independent 17 and antigen-specific 18,67-70
Cell vehicle targeting strategies JC Roth et al effector T-cell populations. Knowledge of naive T-cell trafficking patterns was also recently used in an animal model to target virus to lymph node metastases. 15 These studies demonstrate how the mobility and unique trafficking pathways of lymphocytes can be used to target a variety of tissues. However, expansion of T cells to numbers required for therapeutic efficacy can take a significant amount, especially antigen-specific populations. Thus, other leukocyte populations may be more appropriate for time-sensitive applications.
Neutrophils. Neutrophils may also serve as efficient vehicles for biological targeting strategies. Neutrophils are easily obtained in large numbers and they can rapidly home to a variety of tissues in response to injury or infection. Neutrophils develop and mature in BM and are the primary innate effector cells of the myeloid lineage. During homeostasis neutrophils enter circulation only after they become lineage committed and mature. Nonactivated cells are rapidly cleared from circulation by apoptosis, or by sequestration back into the BM or liver. Inflammatory signals at sites of injury or infection induce both developing and mature neutrophil pools to rapidly mobilize out of the BM. These signals, primarily CXC chemokines 1 through 8, attract neutrophil migration via their CXC receptors 1 and 2. 71 The mobilized neutrophils are the first leukocytes to infiltrate the inflamed tissues where they then act to engulf invading microbes. Phagocytosed microbes are destroyed by an array of oxidative free radicals and other toxins produced in the neutrophil phagosomes. These reactive oxygen species and proteinases can also damage surrounding tissues. 72, 73 Therefore, after carrying out their function at the inflammatory site, the neutrophils rapidly apoptose and are phagocytosed by resident macrophages. 74 This rapid response to inflammatory signals has led to the proposed use of neutrophils as vehicles for delivering therapeutics to sites of infection or injury. 75 However, transplanted cells do not always localize to the sites of interest. Suratt et al. 76 characterized inactive and activated neutrophil populations after transplant. These studies determined that inactive cells home to the BM, whereas prestimulated cells primarily localized to liver. Small numbers of the BM-localized cells could be mobilized in response to inflammation. However, homing of transplanted neutrophils to existing sites of inflammation is inefficient. 76 This is likely due to the rapid rate in which endogenous cells are targeted to these sites and effectively outcompete the infused vehicles. The relatively short life span and poor transduction efficiency of neutrophils will also likely limit their potential as gene-based therapeutic delivery vehicles. However, they may serve as possible vehicles for delivering pharmaceutical compounds to liver or BM.
Monocytes. Monocytes represent another class of circulating phagocytic cell precursors that may have potential as biological targeting agents. Monocytes arise from a common myeloid progenitor in the BM and can differentiate into both macrophage and dendritic cell lineages. 77, 78 Like neutrophils, monocytes are mobilized and home to tissues in response to inflammatory signals. However, monocyte infiltration is typically delayed compared to that of neutrophils. After localization, monocytes can differentiate into a heterogeneous population of phagocytic cell types, including microglial cells, Langerhans cells, and Kupffer cells, as well as peritoneal and alveolar macrophages. The macrophage subsets are primarily innate effector cells that function to remove dead cells and pathogens by phagocytosis. Dendritic cell subsets phagocytose similar particles, but are mainly geared toward priming adaptive immune responses. Upon activation, dendritic cells migrate through afferent lymphatic vessels to regional lymph nodes where they prime T cells. Except for movement to lymph nodes, the differentiated macrophage and dendritic cell populations are not highly mobile and do not typically reenter the circulatory system.
In addition to their role in innate immunity, monocytes and macrophages have also been directly associated with a number of inflammatory diseases including, atherosclerosis, 79 arthritis 80 and diabetes. 81 Macrophages are also the major leukocyte component in many tumors, and secrete intermediates that promote angiogenesis and inhibit immunity. 82, 83 Their involvement in these diseases suggests that macrophages and monocytes may be ideal vehicles for targeting these pathologies. Studies evaluated the use of macrophages as vehicles for targeting inflammation and cancer. 84, 85 However, macrophage localization patterns are distinct from their monocyte precursors. Intravenous infusion of macrophages results in their initial entrapment in the lungs, after which the cells are cleared in the liver and spleen. 84, 85 The presence of inflammatory lesions was shown to enhance transplanted macrophage recruitment, but only moderately. 84, 86, 87 The limited ability of macrophage populations to circulate is likely due to the morphological changes that accompany their differentiation, such as increased size, shape and granularity. 88 However, their monocyte precursors are highly mobile and can home directly to sites of inflammation, including atherosclerotic plaques 89 and cancer. 90 Monocytes comprise 5-10% of the leukocytes in circulation, but this population can be further divided into additional subsets, based on varying chemokine and adhesion molecule expression levels. 91 For example, the CX3CL1 chemokine receptor (CX3CR1) expression levels distinguish monocytes that are replacing phagocyte turnover (CX3CR1 hi ) from those that are homing to sites of inflammation (CX3CR1 lo ). 78 Whereas CX3CL1 acts to recruit monocytes to normal tissue, CCL2 (MCP-1) is the primarily chemokine recruiting monocytes to inflamed tissues. 92 CCL2 expression is also linked to a number of inflammatory diseases. [93] [94] [95] [96] These data suggest monocytes may be the ideal cell vehicles for biological targeting to inflammatory diseases. However, it may be challenging to obtain clinically significant numbers of therapeutically loaded monocytes without culture-induced changes in their phenotype.
Stem cells. A number of adult stem cell populations have now been identified in a variety of tissues, or circulating at low levels during homeostasis. These cells are minimally defined by their ability to both self-renew and give rise to differentiated progeny. For cell therapy end points, early or immature stem cell populations are desirable, as these cells have greater proliferative potential and are less committed to a particular program of differentiation. In addition to the specific cell types they generate, the ease in which stem cells are isolated, expanded and manipulated is also important determiCell vehicle targeting strategies JC Roth et al nant of their therapeutic potential. For cell vehicle applications, the type of progeny the stem cells give rise to may be less critical than their capacity to circulate and deliver therapeutics to a particular target tissue. In this regard, adult stem cells that naturally circulate are likely to be better suited as biologically targeted cell vehicles.
The BM serves as a reservoir for several adult stem cell populations, including those committed toward HSCs, MSCs and endothelial (EPCs) lineages. In addition to survival factors, BM stromal and endothelial cells secrete chemokines that potentiate stem cell homing and retention in the BM. CXCL12 (SDF-1) is the main chemotactic signal driving stem cell recruitment and accumulation in the BM. 97 Hypoxia-specific transcriptional elements control CXCL12 expression levels. 98, 99 Thus, in addition to the hypoxic regions of the BM, stem cells can also be recruited toward elevated CXCL12 levels in ischemic tissues and tumors. 98, 100 The cytokine and growth factor profile of many tumors resembles that of a wound. Not surprisingly, inflammatory cytokines have also been shown to enhance stem cell engraftment in tumors. [101] [102] [103] The hypoxia-targeting property of stem cells has sparked renewed interest in the use of these cells for targeted tissue repair, 104, 105 and therapeutic gene expression in tumors. 106, 107 The circulating fraction of stem cells are ideal candidates for these therapies since their proteome is primed for trafficking. Cytokines, myelosuppressive drugs and synthetic molecules that directly or indirectly perturb CXCL12/CXCR4 interactions have been shown to increase the concentration of these circulating stem cell populations. [108] [109] [110] This phenomenon has been utilized clinically as a strategy to increase the total number of stem cells that can be collected from peripheral blood for myelosupportive BM transplants. 110 However, the fact that these cells can be artificially mobilized into the periphery suggests that isolation and reinfusion of these cells may not be necessary for therapeutic outcomes. In this regard, BM cell mobilization has also already been shown to enhance postinfarct cardiac repair. 104, 105, 111 Nevertheless, isolation and loading the mobilized cells with ectopic agents may enhance their therapeutic utility. For cancer treatment end points, stem cell mobilization should be used with caution. Mobilized CD34 + HSCs were shown to increase tumor growth in murine lymphoma xenografts. 112 Similar observations were noted after MSC transplants. 113 However, to our knowledge, these effects have not been observed clinically. Nevertheless, concern over possible tumor-promoting activity with the use of stem cell vehicles should be alleviated if the therapeutic payload is eventually toxic to the vehicle, as is the case with many oncolytic viruses.
Localized survival and proliferation improves targeting
Since we have broadly defined cell targeting as any means of increasing the localized concentration of cells in target tissues, strategies that enhance survival or proliferation of transplanted cells in these tissues can also be considered as targeting. The proliferative potential of stem cells makes them ideal cell vehicles for this targeting strategy. However, the vast excess of endogenous stem cell numbers might outcompete transplanted cell vehicles for engraftment. This is particularly true if endogenous homing pathways are required to localize the cell vehicle to the site of pathology. Therefore, strategies that confer a survival or proliferative advantage specifically to the cell vehicle population in vivo should increase their preferential engraftment.
Several strategies have already been evaluated for enriching gene-modified HSCs in vivo. Many of these strategies are based on gene products that induce HSC proliferation. 114, 115 Ectopic expression of endogenous HSC genes, including homeobox transcription factors, can boost proliferation, but is likely limited to HSC-based therapies. 115 Recombinant gene products, such as selective amplifier genes, have also been developed and evaluated for HSC gene therapy applications, 114 ,116 but may have broad utility for a range of cell vehicle-based applications. Selective amplifier genes are chimeric constructs consisting of a dimerization domain fused to that of a signaling domain. Dimerization is initiated by synthetic compounds, which then activate the signaling domains to induce cell proliferation. This strategy allows pharmacological control over cell vehicle proliferation, but it does not restrict proliferation to cell vehicles in the target tissue. Nevertheless, similar strategies can be envisioned to selectively enhance cell vehicle proliferation in target sites, especially if dimerization can be initiated by factors unique to the site of pathology.
A variety of survival factors have been evaluated for use in cell therapy applications that might also have potential for improving cell vehicle strategies. Drugresistant genes have been effective for selective enrichment of modified HSCs in vivo. 117, 118 These strategies might also have potential for cell vehicle applications aimed at treating cancer. These drug-resistant genes provide protection from chemotherapeutic agents. Therefore, selective enrichment of drug-resistant cell vehicles could be coupled to drug treatment regimens aimed at controlling cancer growth. Ectopic expression of antiapoptotic genes, such as AKT and Bcl-2, has also been evaluated to improve therapeutic cell survival in vivo (BCL2). [119] [120] [121] [122] Similarly, ectopic expression of the catalytic domain of human telomerase reverse transcriptase has been evaluated as a strategy to limit proliferative senescence in primary cell populations. 123, 124 Despite their potential for enhancing therapeutic cell survival and proliferation, many of these gene products are also associated with malignant transformation. Therefore, nonconstitutive or pharmacologically regulated expression strategies may be required to ensure safety.
Affinity-based interactions can be used for cell targeting
Affinity-based targeting is dependent on binding interactions. This type of targeting takes advantage of molecules that have affinity for specific receptors (such as tumor-specific receptors). Much of the groundwork for affinity-based targeting approaches has been established in the field of viral gene delivery. Viral vectors are efficient gene transfer agents, but they typically have undesirable biodistribution patterns in vivo. Further, they often utilize receptors that are ubiquitously expressed on many cell types. This disseminates gene transfer, and dilutes the therapeutic gene in the intended cell population. Therefore, means to improve the specificity of viral vectors were investigated. Virus targeting has been 128 have all been used as targeting moieties. All of these molecules can be used to alter the tropism of viral agents and achieve cell-specific virus binding/infection. Parallels between virus and cell-based delivery provide a rationale for cell targeting and insight into the types of binding moieties that can be utilized.
The highest binding abilities, in terms of specificity and affinity, have been obtained using molecules that have immune-based recognition functions, such as antibodies or TCRs. These molecules have specifically evolved for binding-based 'recognition' capacities. Therefore, most of the affinity-based targeting approaches utilize these immune molecules or their derivatives to achieve specific delivery. One of the smallest antibody derivatives is the single chain antibody (scFv). These molecules have been extensively evaluated as targeting moieties in both viral and nonviral vectors. 126, 129 Additional molecules, called bispecific adapters, are engineered with binding specificities for both the therapeutic and the target. Bispecific adapters have been used to achieve virus targeting by conjugating virus to unique receptors on the cells of interest. 130 In fact, distinct targeting gains with adenoviral vectors in vivo have only been obtained through the use of bispecific adapters. 12 A pioneering attempt to graft a TCR-binding domain in adenovirus has also been reported. 131 Artificial receptors. Affinity-based cell targeting has mainly been applied to lymphocytes (T, NK and cytokine-induced killer (CIK) cells). This approach is often termed 'targeted' adoptive immunotherapy, whereby the active targeting mechanism is added to redirect the native killing function of an immune cell to the defined target cell. Strategies aimed at redirecting lymphocyte specificity are based on chimeric TCRs or bispecific adaptors. 19, 132 Both of these strategies have improved in the past few years. Chimeric receptors are complex molecules that are endowed with artificial antibody-type or TCR-type specificity and T-cell functionality. Generally, they are a combination of two domains, one is either the recombinant TCR complex (TCR-a and -b) or the variable region of a monoclonal antibody, and the other is a T-cell signaling chain, such as TCR-z. The design of these receptors has been advanced through several optimization stages to achieve increased binding 133 or to enhance T-cell function upon this binding. 134, 135 The feasibility of engineering antitumor specificity into T cells has been demonstrated by several groups, and an array of chimeric receptors, mostly with specificity for different tumor markers have been tested for biological function in vitro. [136] [137] [138] Moreover, the antitumor potency of human lymphocytes expressing cancer-specific chimeric receptors has been demonstrated in vivo in preclinical animal models. 134 So far, partial and complete remission of cancer has been reported in vivo as a result of targeted adoptive immunotherapy with engineered T lymphocytes. 134, 139 Currently, this strategy has reached the stage of clinical translation of Phase I trials. 140 Adapters. Another affinity retargeting strategy for cell carriers is based on the use of molecular adapters that link the specificity of two antibodies into a single agent, or bispecific antibody. Similar to the chimeric receptors described previously, these agents have been used to redirect effector cells (T and NK) to tumor cells in wellcharacterized mechanism of antibody-dependent cellular cytotoxicity (ADCC). ADCC represents a combination of humoral and cellular immunity that utilizes an immune mechanism of cell killing whereby effector cells elicit a cytotoxic response upon binding to the Fc portion of the antibody. The antibody molecule in this approach is acting as a bridge between the target and effector cells and has dual specificity to bind both participants. The Fc portion of the antibody interacts with the cellular Fc receptors. These Fc receptors are divided into Fca-, Fceor FcgRs, depending on their specificity for IgA, IgE or IgG, respectively. 141 The expression pattern of these receptors is specific for defined subsets of mononuclear cells (macrophages, NK cells and granulocytes). Thus, the second portion of the bispecific molecule can be chosen to specifically recruit a specific subset of effector cells, depending on the effector function you want to initiate upon binding (phagocytosis, cytokine production or cytotoxicity). For example, in addition to the IgG receptors FcgRI (CD64) and FcgRIII (CD16), which are often used to recruit T and NK cells, the myeloid receptor for IgA (FcaRI, CD89) has also been tested utilizing an ADCC approach. FcaRI is constitutively expressed on effector cell populations, such as monocytes/macrophages, eosinophils, neutrophils and some types of dendritic cells. 142 Activation of FcaRI was shown to trigger phagocytosis, respiratory burst, cytokine release and ADCC. Stockmeyer et al. 143 demonstrated that neutrophils can also effect malignant B-cell killing via FcaRI and CD20 targeting. Thus far, most of the bispecific adapter strategies have only been applied to redirect endogenous effector cell cytotoxicity or to recruit endogenous cells to the site of bispecific antibody binding. Only a few studies have described the use of an adapter-based approach to coat cell vehicles ex vivo for targeting in vivo. [144] [145] [146] In one of these studies, Blanco et al. 144 utilized irradiated 293T cells as producers of two separate bispecific adapters: one adapter recognized the human carcinoembryonic antigen (CEA) and the CD3-n chain of the TCR, and the other adapter was comprised of a bivalent anti-CEA diabody fused to the extracellular domain of the B7.1 costimulator molecule. The combined use of both adapters served to conjugate and activate human T-cell proliferation and cytotoxicity toward CEA-expressing tumor cells. Further, growth of tumor xenografts, established by cotransplanting adapter-producing cells with CEA-positive carcinoma cells, was inhibited upon infusion of preactivated peripheral blood lymphocytes. Although the idea of direct intratumoral expression of targeting molecules is attractive and allows the feasibility of adapter-based T-cell targeting to be established, it does not stringently assess the targeting ability of the adapters in vivo. This strategy was subsequently improved by the development of a 'selfarming' approach in which the T cells themselves were coated with the adapters. 145 These studies involved bispecific antibodies that conjugated CD3 expression on T cells to Her2 or CA125 ovarian cancer antigens. 146 Activated CIK cells coated with these adapters were able to mediate cytotoxicity toward primary ovarian cancer cells in vitro and in murine xenograft models. 146 Cell vehicle targeting strategies JC Roth et al Our group has been evaluating the use of adapters and artificial receptors (ARs) to superimpose affinity-based cell targeting activity in cells that lack adaptive immune recognition mechanisms, such as MSCs, mast cells and neutrophils. For immunological effector cells, this affinity-based targeting can direct toxicity toward the target cell. However, the consequences of affinity-based targeting with noneffector cell types will depend on the nature of both the cell vehicle and the intended target cell population. Thus, if targeting is achieved, the cell might simply adhere to the target or it might trigger a variety of secondary effects that recruit effector cells or molecules. For cell vehicle strategies the therapeutic effect can also be mediated by the payload the cell delivers. Thus, to compensate for the lack of inherent effector activity with our targeted cell vehicles, they can be armed with recombinant genes or a viral payload.
The ARs we are evaluating consist of the Igk secretory signal fused to the membrane-spanning domain of the platelet-derived growth factor receptor. These basal elements allow binding domains to be expressed on the cell surface. This surface-based scFv expression was previously used to immobilize and purify transiently transfected cell populations. 147 Adenovirus-and lentivirus-mediated expression of these receptors facilitates cell-cell binding activities in vitro and in vivo (Pereboeva et al., unpublished). We are currently evaluating whether cell vehicles expressing these receptors have enhanced tumor targeting and therapeutic delivery in animal tumor models. In this regard, MSCs expressing ARs with specificity to erbB2 have enhanced binding activity toward ovarian tumor cells that overexpress erbB2 in vitro. Moreover, this strategy showed some benefits in targeted cell retention when tested in an in vivo animal model (Pereboeva et al., unpublished). Since MSCs have inherent tumor homing, it will be interesting to evaluate whether affinity-based targeting strategies improve MSC engraftment levels.
The adapters we are evaluating have specificity to tumor antigens and either mast cell or neutrophil surface proteins. Unlike monocyte and lymphocyte populations, neutrophils and mast cells are not often a major component of the tumor-infiltrating leukocyte population. However, their ectopic localization in the tumor may act to recruit other effector cell populations. If not, we will evaluate whether these cells can be loaded with therapeutic factors. Preliminary studies have shown that these adapters mediate cell-cell binding activity in vitro (Pereboeva et al., unpublished) and we are currently evaluating this strategy for targeting tumors in animal models.
Reported attempts at grafting nonimmune cells with artificial specificity are limited. To date, only a few applications have demonstrated the feasibility of using scFvs as a binding moiety in nonimmune cell contexts. A retargeting strategy using an AR was recently applied to primary human monocytes. 148 The chimeric receptor in this study was composed of an scFv molecule, with specificity to CEA and the cytosolic domain of human CD64. The chimeric receptor allowed monocytes to be targeted to CEA-expressing tumor cells, and the cytosolic CD64 domain initiated ADCC activity in response to binding. Another study evaluated the possibility of using red blood cells (RBCs) as targeted cell vehicles. 149 In this study the RBCs were surface-loaded with glycosylphosphatidylinositol-anchored anti-CD40 scFv fragments and evaluated for binding to CD20 + tumors. Other studies have surface-expressed scFvs on cells to create an AR for viral infection 150 or to enhance the potential of tumor cells as drug delivery vehicles. 151 Preconditioning the target sites can improve cell targeting efficiencies
All of the targeting strategies described above are centered on modifying or exploiting the cell vehicle to increase their concentration at the sites of interest. However, the site of pathology can also be preconditioned to be more 'transparent' or more accessible to the cell vehicles. One example of a preconditioning strategy comes from a multistep pretargeting approach developed for cancer therapy. 152 Pretargeting of tumors is achieved by virtue of bispecific antibodies that have two binding motifs, one of which is directed to the tumor antigen. This antibody is not therapeutic or diagnostic on its own, but it binds to the tumor first and preconditions the tumor to bind a secondary therapeutic, such as a radioisotope, drug or toxin. Another strategy for preconditioning is based on the stimulation of chemokine production in the target area, which can be done by local irradiation, 102 gene transfer or other methods. Cells that can specifically home toward these signals are then used as vehicles to deliver therapeutics to the preconditioned site. For example, expression of the chemokine CCL3 in tumor cells has been used to recruit effector T-cell infiltration. 153 Another strategy to modify the target environment is to enhance its permeability, either locally (transient increase the blood-brain barrier permeability) or systemically. In the first case, pretreatment with bradikinin has been shown to enhance the ability of infused monocytes to infiltrate the brain. 154 Thus, monocytes might be effective vehicles to deliver therapeutics into the central nervous system. Monocyte/ macrophage can also be recruited to infiltrate skin in response to UV-induced sunburns. 155 This has been shown as an effective means to enhance genetically modified monocyte recruitment to the skin in murine models. 156 Strategies that modify the visibility and accessibility of target sites are gaining attention and will have great potential for enhancing cell targeting and cellbased therapeutic delivery.
Summary
The importance of effective carriers for in vivo biotherapeutic delivery cannot be argued. In this regard, mammalian cells have been included in the list of potential drug carriers and have been tested for delivering a variety of agents. Early applications utilized the cells as mere therapeutic capsules and therefore did not realize their true potential as therapeutic delivery vehicles. However, this simplistic view is now being challenged. It is becoming clear that to fully harness all of the benefits that a specific cell carrier may offer, different aspects of cell biology have to be taken into consideration. Thus, to realize the potential benefit of active therapeutic delivery to specific sites in vivo, it must be understood that cells are not neutral carriers and they are amenable to various targeting strategies. In this review, we highlighted different cell targeting strategies, including physical, physiological and biological methods that increase the concentration of the cell vehicle in the target site.
The advantages of cell targeting are obvious. However, practical application of this strategy in complex in vivo systems has yet to be fully realized. Biological targeting involves complex and knowledge-driven approaches that are based on selective cell trafficking pathways, cell recognition and binding specificity for target tissues, and improving cell survival in the environment of the target tissues. Some steps toward conferring biological targeting properties to cell carriers have been undertaken, but the complexity of native or engineered cell homing has limited rigorous implementation of this type of cell targeting. Continued dissection of native cell mobilization and homing pathways, during homeostasis and in response to key stimuli, will provide vital information about the types of cells that can be used as naturally targeted vehicles and will help to further develop cell targeting strategies.
Native and artificial strategies for targeting and engrafting cell vehicles to specific sites or tissues might prove valid. In this regard, engineered affinity-based targeting strategies may be less complicated. Further, the availability of a variety of targeting reagents makes this strategy a promising approach for further development. Finally, the combination of physical and biological targeting strategies that are in development for cellbased therapeutic delivery could be more efficient than each alone. Although each of these strategies individually enhances delivery, the combined use of multiple targeting strategies will likely be needed to maximize both the efficiency and specificity of cell-mediated therapeutic delivery.
